Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers
暂无分享,去创建一个
[1] J. McAlpine,et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. , 2019, Gynecologic oncology.
[2] P. Goodfellow,et al. Mismatch repair deficiency identifies patients with high‐intermediate–risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker , 2018, Cancer.
[3] J. McAlpine,et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? , 2018, Gynecologic oncology.
[4] A. Spurdle,et al. Endometrial cancer risk and survival by tumor MMR status , 2018, Journal of gynecologic oncology.
[5] A. Spurdle,et al. ER and PR expression and survival after endometrial cancer. , 2017, Gynecologic oncology.
[6] Wei Chen,et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. , 2017, Gynecologic oncology.
[7] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[8] D. Tritchler,et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Yoshikawa,et al. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. , 2016, Gynecologic oncology.
[10] R. Broaddus,et al. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[11] Wei Zhang,et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis , 2015, World Journal of Surgical Oncology.
[12] A. Talhouk,et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.
[13] Alexander M. Metcalf,et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] X. Matías-Guiu,et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. , 2013, Critical reviews in oncology/hematology.
[15] South East Water. Who we serve , 2012 .
[16] H. Harris,et al. NKT Cells in Sepsis , 2010, Clinical & developmental immunology.
[17] Poonam K Sharma,et al. Current Hypotheses on How Microsatellite Instability Leads to Enhanced Survival of Lynch Syndrome Patients , 2010, Clinical & developmental immunology.
[18] I. Jacobs,et al. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. , 2000, Cancer research.
[19] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .